This higher risk level in health/pharma companies shows up in the way VCs structure their investments. In an early-stage round of financing for a software company, all the investors may dilute the founders by around 15 to 30 percent of the company’s stock. For a typical early-stage pharma or biotech company, investors may dilute the founders at a h
... See moreAli Tamaseb • Super Founders: What Data Reveals About Billion-Dollar Startups
Kauffman Fellows • Venture Fund Portfolio Construction | Journal | Kauffman Fellows
Juan Orbea added
Valuations are a big mystery to many entrepreneurs. And for good reason. In the early stages, valuation is not a factor of revenue or much else. According to research done by Ilya Strebulaev, a professor of venture capital at Stanford Graduate School of Business, and his collaborators, most VCs, especially early-stage VCs, don’t use techniques such
... See moreAli Tamaseb • Super Founders: What Data Reveals About Billion-Dollar Startups
Alex Danco • It’s Not Debt, It’s Better: an Interview with Harry Hurst of Pipe
sari added
Kauffman Fellows • Venture Fund Portfolio Construction | Journal | Kauffman Fellows
Juan Orbea added
Due to the fund economics of early stage investing it may not make sense to do a pro-rata, or follow-on investment with a $5M Series A in order to maintain our 20 percent. As the entrepreneur continues to raise capital, the early stage investors will continue to experience a valuation dilution or divergence in their investor shares, effectively cha
... See moreBradley Miles • #BreakIntoVC: How to Break Into Venture Capital And Think Like an Investor Whether You're a Student, Entrepreneur or Working Professional (Venture Capital Guidebook Book 1)
Both Sides of the Table • What Does the Post Crash VC Market Look Like?
Juan Orbea added